Introduction
============

Renal cell carcinoma (RCC) is one of the most common malignant urologic tumors worldwide. Furthermore, in recent years, RCC has been associated with increased morbidity in China, leading to an estimated 66,800 new cases and 23,400 deaths in 2015 [@B1]. Clear cell RCC (ccRCC), which accounts for about 70% of all cancers of the kidney [@B2], is the major subtype. Diagnosis of RCC mainly depends on imaging tests, and when necessary, a renal biopsy is recommended [@B3]. For the treatment of localized RCC, partial or radical nephrectomy is still the first choice. Immunotherapy and targeted therapy may also be taken into consideration when surgery alone is not enough [@B3]. However, these treatment measures still have some limitations, and new ways to diagnose and treat RCC are greatly needed.

In recent studies, several mutated genes including *PBRM1*, *SETD2*, *KDM6A*, *BAP1,* and others, have been identified as having an impact on the outcomes and biological properties of RCC [@B4]-[@B6]. Among these genes, BRCA1-associated protein-1 (*BAP1*) has been reported to have tumor suppressor activity, which has drawn a lot of interest and may be a target for RCC treatment [@B7]. BAP1, as a deubiquitinating enzyme, exerts its tumor suppressor activity based on its deubiquitinating activity and nuclear localization, which involves the NH2-terminal ubiquitin COOH-terminal hydrolase (UCH) domain and nuclear localization signal (NLS), respectively (**Figure [1](#F1){ref-type="fig"}A**). As previously reported, BAP1-deficient cancer cells were more vulnerable to γ-radiation and more sensitive to olaparib, which indicated that radiotherapy and PARP inhibitors may be more effective in BAP1-mutated cases than in BAP1 wild-type cases [@B8], [@B9]. BAP1 loss leads to ubiquitinated H2A accumulation, causing various abnormal transcriptional changes. Histone deacetylase inhibitors may reverse this phenomenon [@B8]. In addition, a comprehensive understanding of pathway changes caused by *BAP1* mutations may also be useful in filtering potential therapeutic targets.

Previous studies revealed that in ccRCC patients, *BAP1* has a high mutation rate in somatic cells [@B7], [@B10] and *BAP1* germline mutations will lead to a hereditary renal carcinoma syndrome. [@B11], [@B12] Furthermore, low expression of BAP1 usually predicts a poorer prognosis in ccRCC patients. [@B13]-[@B16] Recently, a phase II trial (NCT03207347) was registered to evaluate the treatment response of the PARP inhibitor, niraparib, in *BAP1*-mutated cancer patients, including RCC patients, because BAP1 protein is intimately involved in DNA double-strand break repair. This trial may provide a novel therapeutic strategy to improve the prognosis in *BAP1*-mutated patients.

In this study, we analyzed 445 ccRCC cases using the complete gene expression data and somatic *BAP1* mutation data retrieved from The Cancer Genome Atlas (TCGA) database. We performed a comprehensive analysis including survival, transcriptome, and methylation between *BAP1*-mutated and wild-type cases, and highlighted pathways and molecules related to *BAP1* mutations.

Material and methods
====================

Data retrieval
--------------

The Cancer Genome Atlas (TCGA) Provisional clinical data, mRNA expression profiles, gene methylation data, and somatic mutation data of ccRCC cases were downloaded from the CbioPortal [@B17], [@B18] (<http://www.cbioportal.org/>. Downloading date: 2017-01-16). The Cancer Genome Atlas (TCGA) is a collaboration between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). In the TCGA database, there are multiple types of bioinformation, including transcriptional data, epigenetic data, genomic mutation profiles, and clinical data, across more than 30 cancer types involving \>10,000 patients in total. Specifically, the TCGA ccRCC project contained 538 cases. We excluded cases without gene expression data (generated by RNA sequencing and shown in pre-normalized Z-scores) and somatic *BAP1* mutation data (generated using genome sequencing). We also excluded one ccRCC case with a *BAP1* mutation that was not in the UCH domain or NLS. Finally, 445 ccRCC cases were entered in our analysis, including 39 cases with *BAP1* mutations and 406 cases with wild-type *BAP1*.

Study design
------------

First, we performed a survival analysis using TCGA clinical data. Then, we focused on transcriptome data and analyzed differentially expressed genes (DEGs) between somatic *BAP1*-mutated and wild-type cases. After DEG screening, we carried out Gene Ontology (GO) functional analysis [@B19], Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis [@B20], and protein-protein interaction (PPI) and module analysis (**Figure [1](#F1){ref-type="fig"}B**). Additionally, we performed a gene methylation analysis of these cases.

Survival analysis
-----------------

To test overall survival (OS) and disease-free survival (DFS) differences between cases with or without *BAP1* mutations, the Kaplan-Meier method was used to compare survival curves for these two groups. Survival data was censored at five years and *P* values less than 0.05 were considered statistically significant.

Analysis of DEGs
----------------

Gene expression data (mRNA level) were processed using Multi-Experiment Viewer 4.9.0 [@B21]. The Student\'s t test was used to examine differences in expression levels between *BAP1*-mutated and *BAP1* wild-type cases. Only genes with an adjusted P value less than 0.01, FDR less than 0.01, and a mean Z score difference larger than 0.5 were considered DEGs.

Functional and pathway enrichment analysis
------------------------------------------

The Database for Annotation, Visualization and Integrated Discovery (DAVID) is a comprehensive set of functional annotation tools that has been used for systematic and integrative analysis of large gene lists [@B22]. GO terms are significantly overrepresented in a set of genes from three aspects: the cellular component, molecular function, and the biological process [@B23]. In our work, the significant GO biological processes, molecular function terms, and KEGG pathway enrichment analyses of the identified DEGs were performed using DAVID, with the threshold of P values less than 0.05 and enrichment gene counts over 5. For module gene analysis, the P value threshold was also set as 0.05 but the gene count threshold was 2.

Protein-protein interaction (PPI) network construction
------------------------------------------------------

The Search Tool for the Retrieval of Interacting Genes (STRING) database is a pre-computed global resource for the exploration and analysis of PPI information [@B24]. In the present study, the STRING 10.5 online tool was used to screen the PPIs of the DEGs. The DEGs with the required confidence level (combined score) greater than 0.4 were selected, and then the PPI network was constructed and visualized using Cytoscape 3.5.1 [@B25]. Given that most of the networks were scale-free, hub genes were selected with a connectivity degree larger than 10.

Module analysis of the PPI network
----------------------------------

Module analysis was performed on the PPI network using Molecular Complex Detection (MCODE), which finds protein complexes and parts of pathways in a network in Cytoscape with a degree cutoff =2, node score cutoff =0.2, k-core =2, and max depth =100 [@B26]. Then, significant modules with MCODE scores \>4 and nodes \>6 were selected. Next, GO functional and KEGG pathway enrichment analyses of the most significant modules were performed with a threshold of P value less than 0.05.

Gene methylation analysis
-------------------------

Pre-processed gene methylation data (HM450 platform, shown with β values) downloaded from CBioPortal contained 320 tumor samples, including 260 samples in the 445 selected cases in our study and 160 normal kidney tissues. In these 260 samples, 23 of them were from *BAP1*-mutated cases.

With regard to CpG island methylator phenotype (CIMP) analysis, we chose genes that were not methylated in the 160 normal samples (mean β value \<0.1) and that had a standard deviation of greater than 0.1 (364 genes) in the tumor samples used for clustering. Hierarchical clustering with Wald\'s method was used to cluster 260 samples, and the clustering dendrogram was cut into two clusters. One of the two exhibited extensive hypermethylation across selected genes and was renamed the CIMP cluster [@B27].

Ethics statement
----------------

The Research Ethics Committee of Shanghai Medical College, Fudan University, China approved this study. For the public TCGA database, we did not require informed consent of patients.

Results
=======

Patient characteristics and survival analysis
---------------------------------------------

Overall, 445 ccRCC cases were divided into two cohorts (39 patients with *BAP1* mutations and 406 patients without *BAP1* mutations). Demographics and clinical characteristics of these patients were analyzed using the Student\'s t test and Chi-square test (**Table [1](#T1){ref-type="table"}**). The two cohorts were similar in terms of age, laterality, pN stage, and Fuhrman Grade. However, they differed in gender (P=0.003), pT stage (P=0.028), pM stage (P=0.025), and tumor stage (P=0.001).

*BAP1* mutations in these patients are shown in **Table [2](#T2){ref-type="table"},** and the total mutation frequency was 8.76% (39/445). Among 538 ccRCC cases in TCGA, 40 patients carried a somatic *BAP1* mutation. Most of the *BAP1* mutations altered the UCH domain or NLS (39/40), and only 1 out of 40 mutation sites did not involve these two regions, which suggested that mutations in the UCH domain or NLS may play a role in tumorigenesis.

Cases in the *BAP1*-mutated and *BAP1* wild-type groups showed different prognoses (**Figure [2](#F2){ref-type="fig"}**). Kaplan-Meier curves of 5-year OS and DFS between mutated and wild-type groups indicated that ccRCC patients with somatic *BAP1* functional mutations had a significantly shorter OS (P=0.035) and DFS (P=0.036).

Identification of DEGs
----------------------

By processing gene expression data (mRNA level), we found a total of 1,799 DEGs between *BAP1*-mutated and *BAP1* wild-type cases. Among them, 583 were upregulated DEGs, while 1,216 were downregulated DEGs.

GO functional and pathway enrichment analysis
---------------------------------------------

The significant GO biological processes and molecular function term analysis of the identified DEGs were carried out using DAVID. In all, upregulated DEGs were mainly enriched in 25 GO functions and downregulated DEGs were mainly enriched in 96 GO functions. The most significant 10 GO terms for these two groups of DEGs are listed in **Figures [3](#F3){ref-type="fig"} A & B**. Protein binding was the most significant GO term for upregulated DEGs and metal ion binding was the most significant GO term for downregulated DEGs.

In addition, KEGG pathway enrichment analysis was also performed. Ten pathways for upregulated and 28 pathways for downregulated DEGs were found. The 10 most significant pathways are listed for both groups, as well (**Figures [3](#F3){ref-type="fig"} C & D**).

PPI network, hub genes, and module analysis
-------------------------------------------

The STRING database was used to build up the PPI network of DEGs. Furthermore, 36 hub proteins in the upregulated PPI network and 158 in the downregulated PPI network were discovered. The top 20 hub proteins in each network are shown in **Table [3](#T3){ref-type="table"}**.

In the upregulated PPI, two modules were chosen with MCODE scores \>4 and nodes \>6: Module-Up-A with 21 nodes (MCODE Score=4.50) and Module-Up-B with 9 nodes (MCODE Score=4.25). At the same time, three modules were chosen in the downregulated PPI network: Module-Down-A with 31nodes (MCODE Score=7.67), Module-Down-B with 21 nodes (MCODE Score=6.10), and Module-Down-C with 30 nodes (MCODE Score=4.48) (**Table [4](#T4){ref-type="table"}**). Proteins involved in Module-Up-A and Module-Down-A are shown in **Supplementary Figure [1](#SM0){ref-type="supplementary-material"}**.

GO functional and KEGG pathway analyses of DEGs in Module-Up-A and Module-Down-A were implemented. The results were as follows: In Module-Up-A, DEGs were enriched in GO functions like antigen processing and presentation of exogenous peptide antigen via MHC class II and intracellular protein transport. Regarding the KEGG pathway, it included endocrine and other factor-regulated calcium reabsorption, Huntington\'s disease, and synaptic vesicle cycle pathways. Regarding Module-Down-A, DEGs were enriched in GO functions such as negative regulation of transcription from RNA polymerase II promoter and rRNA transcription. For the KEGG pathway, DEGs tended to be enriched in calcium signaling pathways, cGMP-PKG signaling pathways, and Chagas disease (American trypanosomiasis) pathways (**Tables S1 & S2**).

Gene methylation analysis
-------------------------

Gene methylation data of 260 ccRCC tumor tissues (23 with BAP1 mutations) were clustered and cases were divided into a CIMP cluster and non-CIMP cluster based on the clustering results (**Figure [4](#F4){ref-type="fig"}**). It indicated that *BAP1-*mutated cases compared with *BAP1* wild-type cases had a significantly higher probability of being in a CIMP cluster (60.9% vs. 28.3%, P=0.001).

Discussion
==========

Combined analysis including genome, transcriptome, proteome, and clinical data has been widely used in the field of cancer research. In our study, we comprehensively analyzed ccRCC cases extracted from the TCGA database, focusing on *BAP1* functional somatic mutations. We highlighted several pathways or molecules altered dramatically between *BAP1*-mutated and wild-type cases, which may indicate new diagnostic biomarkers and targets for novel therapy development.

By analyzing hub genes in the upregulated PPI network, we found that TP53, CAD, and translocator protein (TSPO) had the highest connective degree. The *TP53* gene encodes a tumor suppressor protein, which plays a vital role in DNA repair, the cell cycle, and apoptosis. Mutations in *TP53* drives carcinogenesis in various cancers [@B28]. One study indicated that *TP53* overexpression was an independent adverse prognostic factor in laryngeal squamous cell carcinoma [@B29]. TP53 protein levels can be determined using a commercial reverse phase protein array (RPPA). In addition, we examined TP53 protein levels using RPPA data deposited in TCGA and found that there was no significant difference between the *BAP1*-mutated and *BAP1* wild-type groups (**Figure [S2](#SM0){ref-type="supplementary-material"} A**). This indicated that although *TP53* mRNA levels were higher in *BAP1*-mutated cases, a post-transcriptional mechanism was inhibiting mRNA translation. This phenomenon emphasized the importance of performing a comprehensive analysis when using bioinformatics to avoid misinterpretation of the data.

Regarding CAD, it is a multifunctional enzyme, composed of carbamoyl-phosphate synthetase II, aspartate transcarbamylase, and dihydroorotase [@B30]. Previous studies demonstrated that CAD had the potential to be developed as an antitumor target [@B31]. The de novo pyrimidine synthesis pathway is essential for cancer development, and CAD controls the first three steps in the pathway. Activity of CAD is further modulated by phosphorylation through the ERK-MAP kinase, cAMP-dependent protein kinase, and mTOR signaling cascade. Thus, the mTOR inhibitor everolimus and temsirolimus may be used to inhibit mTOR signaling and thereby inhibit CAD activity to block cancer cell proliferation. Furthermore, the structure of CAD has been determined recently. The structural data suggests that targeting the dihydroorotase domain of the human CAD protein may have antitumoral potential. In accordance with the upregulation of CAD in ccRCC, one study also revealed that CAD expression was increased in invasive and relapsing androgen-dependent tumors [@B32].

Regarding TSPO, it is a cholesterol- and drug-binding protein primarily located in the outer mitochondrial membrane. TSPO not only plays an important role in steroidogenesis, but also has a direct or indirect link with multiple other cellular functions including apoptosis, cell proliferation, differentiation, anion transport, porphyrin transport, heme synthesis, and regulation of mitochondrial function [@B33]. Based on these characteristics, TSPO-binding chemicals have exhibited an inspiring effect in PET imaging and anticancer therapies[@B34]. TSPO-binding drugs have also been demonstrated to cause death of several cancer cells, and TSPO has already been viewed as a novel target for cancer chemotherapy [@B35].

In evaluating the downregulated PPI network, we found CTNNB1 and MAPK3 to have the highest degree of connectivity. CTNNB1 is responsible for encoding β-catenin, which is a multifunctional protein that plays a significant role in maintaining physiological homeostasis. β-catenin not only maintains the integrity of epithelial tissues but also directs transcription of various genes on extracellular instigations [@B36]. In RCC patients, low expression of β-catenin was related to venous growth inside the tumor, extratumoral venous growth, and perineural growth. Furthermore, downregulated membranous expression intensity of β-catenin was predictive of a shorter recurrence-free survival (RFS), indicating that β-catenin could become a biomarker of aggressiveness in RCCs [@B37]. We also examined CTNNB1 protein levels between groups, and the differential expression observed was statistically significant (**Figure [S2](#SM0){ref-type="supplementary-material"} B**).

Mitogen-activated protein kinase (MAPK3) plays an important role in one of the MAPK pathways, which regulate cell proliferation, differentiation, migration, and apoptosis. Several studies revealed that positive expression of both MAPK3 and AMPK were associated with a better prognosis in several cancers [@B38], [@B39]. These findings suggested that low expression of MAPK3 showed potential as a worse prognostic indicator.

Recently, *BAP1* was reported to be mutated in up to 14% of sporadic ccRCCs and was associated with more aggressive tumors and poorer patient outcomes [@B9], [@B40]. In addition, ccRCC with a pathogenic germline *BAP1* mutation has already been defined as a tumor predisposition syndrome [@B41]. It is unlikely that biopsy and genetic profiling of *BAP1*-mutated cases could change the treatment principle in localized kidney cancer patients; however, for metastatic or locally advanced patients with a *BAP1* functional mutation, this might alter the therapeutic strategy. More clinical trials of new therapies like PARP inhibitors and immunotherapy, for patients with *BAP1* mutations, will appear in the future. Treatment for *BAP1*-mutated cases, especially advanced cases, will become more personalized.

Our study had some limitations. First, all data analyzed in this study were derived from the TCGA database, not from us. Although TCGA is a huge data repository with different dimensions of data, most patients are Caucasian, African, or of Afro-Caribbean descent, and there are few Asian people. Thus, comprehensive analysis of *BAP1* mutation patterns in Asian ccRCC patients is still needed in the future. Second, results of this study were analyzed, clustered, and predicted *in silico*, and not verified using molecular biology experiments. Third, there were only a limited number (39 patients) of BAP1-mutated cases included in this study. Therefore, as a next step, experimental studies based on our findings should be performed.

Conclusion
==========

Our study provides a comprehensive understanding of *BAP1* functional somatic-mutated ccRCC patients, and lists several pathways, biological processes, and molecules that may be involved in the progression and development of *BAP1*-mutated tumors. Furthermore, several top hub genes like *CAD* and *TSPO* may be potential therapeutic targets in *BAP1-*mutated ccRCC.
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![**(A)** Representative BAP1 protein domains with amino acid sequence. (Numbers on the top indicate amino acid position.) UCH: ubiquittin COOH-terminal hydroaase; NLS: nuclear localization signal. **(B)** Flow chart of study design and summary of ccRCC cases filtered in TCGA datasets. TCGA: The Cancer Genome Atlas; DEG: different expression gene; CIMP: CpG Island Methylation Phenotype; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; PPI: protein-protein interaction.](jcav09p4108g001){#F1}

![**(A)** The Kaplan-Meier plot of overall survival (censored at 60 months) in TCGA ccRCC patients (*BAP1* mutation cases versus *BAP1* wild-type cases). **(B)** The Kaplan-Meier plot of disease-free survival (censored at 60 months) in TCGA ccRCC patients (*BAP1* mutation cases versus *BAP1* wild-type cases).](jcav09p4108g002){#F2}

![**(A)** Top 10 significant GO terms (biological process or molecular function) in up-regulated DEGs in *BAP1* mutated cases. **(B)** Top 10 significant GO terms (biological process or molecular function) in down-regulated DEGs in *BAP1* mutated cases. **(C)** Top 10 significant KEGG pathways in up-regulated DEGs in *BAP1* mutated cases. **(D)** Top 10 significant KEGG pathways in down-regulated DEGs in *BAP1* mutated cases.](jcav09p4108g003){#F3}

![A subgroup of clear cell renal cell carcinoma manifests a CpG island methylator Phenotype (CIMP). Molecular subtyping by means of TCGA DNA methylation platform revealed two subtypes of ccRCC, one of which showed widespread DNA hypermethylation patterns characteristic of CIMP-associated tumors. *BAP1* mutation cases had a significantly higher probability to obtain CIMP than *BAP1* wild type cases](jcav09p4108g004){#F4}

###### 

Clear-cell renal cell carcinoma patient demographics and clinical characteristics in TCGA.

  ---------------------------------------------------------------------------------------
  \                     TCGA ccRCC cohort   P value        Total cohort\   
  Characteristics                                          (N=445)         
  --------------------- ------------------- -------------- --------------- --------------
  Age, median (range)   58 (32 - 85)        61 (26 - 90)   0.872 ^a^       60 (26 - 90)

  Number (%)                                                               

  Gender                                                   **0.003 ^b^**   

  Male                  17 (43.6)           273 (67.2)                     290 (65.2)

  Female                22 (56.4)           133 (32.8)                     155 (34.8)

  Lateral                                                  0.417^b^        

  Left                  21 (53.8)           191 (47.0)                     212 (47.6)

  Right                 18 (46.2)           215 (53.0)                     233 (52.4)

  pT stage                                                 **0.028^b^**    

  T1 & T2               18 (46.2)           260 (64.0)                     278 (62.5)

  T3 & T4               21 (53.8)           146 (36.0)                     167 (37.5)

  pN stage                                                 0.069 ^c^       

  N0                    24 (61.5)           180 (44.3)                     204 (45.8)

  N1                    4 (10.3)            10 (2.5)                       14 (3.1)

  Nx                    11 (28.2)           216 (53.2)                     227 (51.0)

  pM stage                                                 **0.025^b^**    

  M0                    28 (71.8)           347 (85.5)                     375 (84.3)

  M1                    11 (28.2)           59 (14.5)                      70 (15.7)

  Tumor stage                                              **0.001^b^**    

  I & II                13 (33.3)           249 (61.3)                     262 (58.9)

  III & IV              26 (66.7)           157 (39.7)                     183 (41.1)

  Fuhrman Grade                             0.087 ^c^                      

  I & II                12 (30.8)           185 (45.6)                     197 (44.3)

  III & IV              26 (66.6)           217 (53.4)                     243 (54.6)

  Unclear               1 (2.6)             4 (1.0)                        5 (1.1)

  \*CIMP                                                                   

  CIMP                  14 (60.9)           67 (28.3)      **0.001 ^b^**   81 (31.2)

  Non-CIMP              9 (39.1)            170 (71.7)                     179 (68.8)
  ---------------------------------------------------------------------------------------

a\. Student\'s t test; b. Chi-square test; c. Chi-square test, exclude unclear cases.

\* Numbers do not sum to total because of missing values.

###### 

*BAP1* mutation summary in TCGA ccRCC cohort.

  -----------------------------------------------------------------
  Characteristics                    *BAP1* mutation carriers in\
                                     TCGA ccRCC cohort (N=39)
  ---------------------------------- ------------------------------
  Mutation frequency, (%)            39/445 (8.76)

  Number of mutation carriers, (%)   

  Mutation type                      

  Missense mutation                  12 (30.77)

  Inframe-shift InDels               0

  Truncating mutation                28 (71.79) ^a^

  Mutation site                      

  Altering UCH domain                11 (28.21)

  Altering NLS                       16 (41.03)

  Altering both UCH domain and NLS   12 (30.77)
  -----------------------------------------------------------------

a\. one ccRCC patient had a missense mutation and a truncating mutation both. One patient had two different truncating mutations. UCH domain: ubiquitin COOH-terminal hydrolase domain; NLS: nuclear-localization signals.

###### 

The hub proteins in the up-regulated and down-regulated protein-protein interaction network. (Top 20 in each)

  Protein Symbol       Degree   Protein Symbol   Degree   Protein Symbol   Degree   Protein Symbol   Degree
  -------------------- -------- ---------------- -------- ---------------- -------- ---------------- --------
  **Up-regulated**                                                                                   
  TP53                 61       DNM2             22       CCT3             18       ORC1             15
  CAD                  49       GRB2             22       CDK16            17       PABPC1           15
  TSPO                 48       SMARCA4          22       BIRC5            15       RFC5             15
  SRC                  42       ALDH18A1         20       CFL1             15       SEC61A1          15
  RAD51                33       DECR1            20       NME2             15       AP2M1            13
  **Down-regulated**                                                                                 
  CTNNB1               76       MAPK8            61       SIRT1            45       PRKACB           37
  MAPK3                69       KDR              56       INSR             42       EDN1             36
  FYN                  68       RHOB             48       EGR1             39       KALRN            36
  HDAC1                64       ITGA2            47       SMARCA2          39       SMAD2            36
  BCL2                 63       KAT2B            47       FLT1             37       SMAD4            36

###### 

Module Analysis of up- and down- regulated DEGs between *BAP1* WT/Mutated cases.

  Modules              No. of DEGs   No. of connections   MCODE Score
  -------------------- ------------- -------------------- -------------
  **Up-regulated**                                        
  Module-Up-A          21            45                   4.50
  Module-Up-B          9             17                   4.25
  **Down-regulated**                                      
  Module-Down-A        31            115                  7.67
  Module-Down-B        21            61                   6.10
  Module-Down-C        30            65                   4.48
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